Leading brokers name 3 ASX shares to sell today

On Monday I looked at three shares that had found favour with brokers and been given buy ratings this week.

But not all shares are in favour right now. For example, the three shares listed below have been given sell ratings by brokers this week.

Here’s why they are bearish on them:

Automotive Holdings Group Ltd (ASX: AHG)

According to a note out of Morgan Stanley, it has downgraded this automotive retailer to an underweight rating and slashed the price target on its shares to $1.55. The broker has made the move after reducing its earnings forecasts for the company on the back of lower growth expectations due to falling vehicle sales. Morgan Stanley believes that a decline in house prices will also lead to a meaningful decline in vehicle sales. I would agree with the broker on this one and think that investors ought to avoid Automotive Holdings.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)

Analysts at UBS have retained their sell rating but lifted the price target on this medical device company’s shares to NZ$12.40 (A$11.44). According to the note, the broker believes that there are downside risks for its shares that the market is ignoring. These include a weak U.S. flu season and legal issues. In addition to this, the broker sees the upcoming IPO of Vapotherm in the United States as a potential competitive threat. I would agree with UBS on Fisher & Paykel Healthcare and believe there are better options elsewhere in the sector.

ResMed Inc. (ASX: RMD)

A note out of the Macquarie equities desk reveals that it has retained its underperform rating but increased the price target on the sleep treatment company’s shares to $13.50 following the release of its first quarter results. Although its results came in ahead of the broker’s expectations, it is waiting for evidence that its growth trends are sustainable before making any changes to its long-term forecasts. While I think Macquarie makes a fair point, I’m confident in its long-term growth prospects and see ResMed as a buy.

While those may be regarded as sells, this top tech share has been labeled a buy.

This tech share has been given a buy rating

Scott Phillips has stumbled upon a little-owned stock he believes could be one of the greatest discoveries of his 25 years as a professional investor.


This is your chance to get in early on of what could prove to be a very special investment recommendation. Think about how many investing trends you've missed out on, even though you knew they were going to be big. Don't let that happen again. This is your chance to get in early.

Simply click here to get started and access our secure sign-up page.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Automotive Holdings Group Limited and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!